作者: Alessio Moriconi , Andrea Aramini , Marcello Allegretti , Riccardo Bertini , Andrea Beccari
DOI:
关键词:
摘要: The present invention relates to selected (R)-arylalkylamino derivatives of formula (I), in which R, R1 and Ar are as defined the claims. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. absolutely lack CXCL8 activity. Said useful treatment pathologies depending chemotactic activation neutrophils monocytes by fraction complement. In particular, sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis prevention injury caused ischemia reperfusion.